Clinical Trials Directory

Trials / Conditions / Chronic Graft vs Host Disease

Chronic Graft vs Host Disease

12 registered clinical trials studyying Chronic Graft vs Host Disease — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingStudy of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Gra
NCT06824103
Novartis PharmaceuticalsPhase 4
UnknownDonor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib
NCT05095649
Fundación Pública Andaluza para la gestión de la Investigación en SevillaPhase 2
TerminatedA Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Partic
NCT04852692
Janssen Korea, Ltd., Korea—
CompletedDonor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease
NCT03683498
Fundación Pública Andaluza para la gestión de la Investigación en SevillaPhase 1
CompletedStudy of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic
NCT02759731
National Cancer Institute (NCI)Phase 1 / Phase 2
Active Not RecruitingAlvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogen
NCT02669251
National Cancer Institute (NCI)Phase 1 / Phase 2
TerminatedBiomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Th
NCT02322190
National Cancer Institute (NCI)Phase 2
UnknownPredictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
NCT02067832
University of British Columbia—
CompletedImpact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
NCT01221766
Dana-Farber Cancer Institute—
CompletedCampath in Chronic GVHD
NCT00495755
Dana-Farber Cancer InstitutePhase 1
RecruitingNatural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Dis
NCT00092235
National Cancer Institute (NCI)—
AvailableExpanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
NCT05544032
Incyte Corporation—